Английская Википедия:Idelalisib

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox

Idelalisib, sold under the brand name Zydelig, is a medication used to treat certain blood cancers.[1][2]

The substance acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase.[3][4] It was developed by Gilead Sciences. Idelalisib had annual sales of $168 million (USD) during the year of 2016, up from $132 million (USD) in 2015.[5] It is taken orally (swallowed by mouth).

Medical uses

Idelalisib is a second-line drug for patients whose chronic lymphocytic leukemia (CLL) has relapsed. Used in combination with rituximab,[6] idelalisib is to be used in patients for whom rituximab alone would be considered appropriate therapy due to other existing medical conditions.[6] It appears to be effective and leads to improvement of lymphadenopathy and splenomegaly. However, the lymphocyte counts take longer to decrease to normal levels with idelalisib. It is not recommended as a first-line treatment.[1]

Adverse effects

Clinical symptoms include diarrhea, fever, fatigue, nausea, cough, pneumonia, abdominal pain, chills and rash. Laboratory abnormalities may include: neutropenia, hypertriglyceridemia, hyperglycemia and elevated levels of liver enzymes. Idelalisib's safety and effectiveness to treat relapsed FL and relapsed SLL were established in a clinical trial with 123 participants with slow-growing (indolent) non-Hodgkin lymphomas. All participants were treated with idelalisib and were evaluated for complete or partial disappearance of their cancer after treatment (objective response rate, or ORR). Results showed 54% of participants with relapsed FL and 58% of participants with SLL experienced ORR.[7]

The U.S. label for idelalisib has a boxed warning describing toxicities that can be serious and fatal, including liver toxicity, severe diarrhea, colon inflammation, lung tissue inflammation (pneumonitis) and intestinal perforation, and the manufacturer was required to put in place a Risk Evaluation and Mitigation Strategy (REMS) under which the risk of toxicities would be managed.[8]

In March 2016, as reports were made from three ongoing clinical trials of serious adverse events and deaths, mostly due to infections, the European Medicines Agency opened a review of the drug and its risks.[9] On March 21, 2016 Gilead Sciences (the manufacturer of idelalisib) alerted healthcare providers about decreased overall survival and increased risk of serious infections in patients with CLL and indolent non-Hodgkin lymphoma (iNHL) treated with idelalisib.[10] The company also disclosed that it stopped six clinical trials in patients with CLL, SLL and iNHL due to an increased rate of adverse events, including deaths.[11] In 2016, the EMA recommended that people on idelalisib should be given medication against the lung infection Pneumocystis jirovecii pneumonia and this should be continued for up to 6 months after idelalisib has stopped. In addition, people should be monitored for signs of infection.[12]

Pharmacology

Mechanism of action

PI3Kδ is expressed in normal and malignant B-cells. By inhibiting it, idelalisib induces apoptosis and prevents proliferation in cell lines derived from malignant B-cells and in primary tumor cells. It also inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5 signaling, which are involved in the trafficking and homing of B-cells to the lymph nodes and bone marrow.[1]

Binding profile

Idelalisib is a competitive inhibitor of the ATP binding site of the PI3Kδ catalytic domain. Its in vitro potency and selectivity relative to the other Class I PI3K isoforms is the following:[13]

PI3K isoform IC50 (nM) IC50-based PI3Kδ-fold selectivity
PI3Kα 8,600 453
PI3Kβ 4,000 211
PI3Kγ 2,100 110
PI3Kδ 19 1

History

Regulatory

In July 2014, the FDA and EMA granted idelalisib approval to treat chronic lymphocytic leukemia.[7][14]

It was also approved by the FDA for the treatment of relapsed follicular lymphoma (FL) and small lymphocytic lymphoma (SLL), both in patients who had received at least two prior systemic therapies.[1] This approval was voluntarily withdrawn by the manufacturer in May 2022 after they failed to complete post-marketing confirmatory studies required by the FDA.[15] This has coincided with the withdrawal of every other PI3K inhibitor for follicular lymphoma: duvelisib in December 2021, umbralisib in January 2022, and copanlisib in November 2023.[16][17][18] These withdrawals are attributed to a possibly detrimental effect on survival seen in multiple studies of this drug class, likely due to toxic side effects.[19]

References

Шаблон:Reflist

External links

Шаблон:Intracellular chemotherapeutic agents Шаблон:Portal bar

  1. 1,0 1,1 1,2 1,3 Ошибка цитирования Неверный тег <ref>; для сносок PI не указан текст
  2. Ошибка цитирования Неверный тег <ref>; для сносок Zydelig EPAR не указан текст
  3. Ошибка цитирования Неверный тег <ref>; для сносок Spreitzer не указан текст
  4. Ошибка цитирования Неверный тег <ref>; для сносок Wu не указан текст
  5. Шаблон:Cite web
  6. 6,0 6,1 Ошибка цитирования Неверный тег <ref>; для сносок nejm не указан текст
  7. 7,0 7,1 Ошибка цитирования Неверный тег <ref>; для сносок FDA6387 не указан текст
  8. Шаблон:Cite web
  9. Шаблон:Cite web
  10. Шаблон:Cite web
  11. Шаблон:Cite web
  12. Шаблон:Cite web
  13. Шаблон:Cite web
  14. Ошибка цитирования Неверный тег <ref>; для сносок EMA не указан текст
  15. Ошибка цитирования Неверный тег <ref>; для сносок Federal Register не указан текст
  16. Ошибка цитирования Неверный тег <ref>; для сносок OncLive не указан текст
  17. Ошибка цитирования Неверный тег <ref>; для сносок FDA news не указан текст
  18. Ошибка цитирования Неверный тег <ref>; для сносок Reuters не указан текст
  19. Ошибка цитирования Неверный тег <ref>; для сносок Richardson не указан текст